Preclinical CRO Market Size To Reach $12.37 Billion By 2033

Preclinical CRO Market Growth & Trends

The global preclinical CRO market size is expected to reach USD 12.37 billion by 2033, registering a CAGR of 8.03% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends. The increasing volume of new drugs entering the preclinical phase is also anticipated to boost the market during the forecast period. However, the COVID-19 pandemic had temporarily affected the market owing to the shutdown of research sites due to the implementation of national lockdowns.

The market is undergoing a series of mergers and acquisitions, resulting in improvement in full-service capabilities and the international reach of larger companies. For instance, in 2019, WuXi AppTec acquired Pharmapace. On the other hand, mid-sized and smaller contract research organizations are focusing on niche sectors and are providing a personalized approach to their sponsors. Various companies are focusing on research and development of new drugs and therefore are outsourcing these activities to launch efficient CRO services in the market. This, in turn, provides a positive atmosphere for joint ventures among market participants owing to the preference of sponsors to maximize their benefits.

The COVID-19 pandemic is ever increasing since the disease was first identified in China in December 2019. Until March 9, 2022, more than 4500 million cases of COVID-19 were reported globally; this pandemic has fast-tracked the development of vaccines and drug testing. There are currently over 195 COVID-19 vaccine candidates in preclinical studies.

 Request a free sample copy or view report summary: Preclinical CRO Market Report

Preclinical CRO Market Report Highlights

• The toxicology testing segment accounted for the largest revenue share in the preclinical CRO industry of 22.45% in 2024. Bioanalysis and DMPK Studies segment is anticipated to grow at the fastest CAGR during the forecast period.

• The Patient Derived Organoid (PDOs) Models segment held the largest market share in 2024. Patient Derived Xenograft (PDX) Models segment is anticipated to grow at the considerable CAGR during the forecast period.

• The biopharmaceutical companies segment held the largest market share in 2024, due to the increasing reliance of pharmaceutical and biotech firms on preclinical CROs to accelerate drug discovery and development processes. Government and Academic Institutes segment is anticipated to grow at the considerable CAGR during the forecast period.

• North America accounted for the largest revenue share of 48.45% in the preclinical CRO market in 2024. Asia Pacific is expected to be the fastest growing preclinical CRO market due to the region’s cost advantages, expanding R&D infrastructure, and a growing pharmaceutical and biotechnology sector in countries such as China, India, Japan, and South Korea.

Preclinical CRO Market Segmentation

Grand View Research has segmented global preclinical CRO market report based on service, model type, end-use, and region:

Preclinical CRO Service Outlook (Revenue, USD Million, 2021 - 2033)

• Bioanalysis and DMPK studies

  • In vitro ADME

  • In-vivo PK

• Toxicology Testing

  • GLP

  • Non-GLP

• Compound Management

  • Process R&D

  • Custom Synthesis

  • Others

• Chemistry

  • Medicinal Chemistry

  • Computation Chemistry

• Safety Pharmacology

• Others

Preclinical CRO Model Type Outlook (Revenue, USD Million, 2021 - 2033)

• Patient Derived Organoid (PDO) Model

• Patient derived xenograft model

Preclinical CRO End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Biopharmaceutical Companies

• Government and Academic Institutes

• Medical Device Companies

Preclinical CRO Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Norway

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Oman

  • Qatar

List of Key Players of Preclinical CRO Market

• Eurofins Scientific

• PRA Health Sciences, Inc. (ICON plc)

• Wuxi AppTec

• Medpace, Inc.

• Charles River Laboratories International, Inc.

• PPD (Thermo Fisher Scientific, Inc.)

• SGA SA

• Intertek Group Plc (IGP)

• LABCORP

• Crown Bioscience